# Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/4-fluoroamphetamine-schedule-i-placement/ > **Published:** 2026-04-13T09:59:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T14:01:33-04:00 > **Clinical Summary:** Learn about 4-fluoroamphetamine schedule I placement and its implications under the Controlled Substances Act by the DEA. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register PolicySafetyResearch Clinical Summary # Clinical Summary This DEA action places 4-fluoroamphetamine, a synthetic amphetamine analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, recognizing it as a drug of abuse with no accepted medical use and high potential for dependence. While this regulation does not directly address cannabis, it reflects the federal government’s ongoing enforcement approach to novel psychoactive substances and reinforces the broader [controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) framework within which cannabis currently remains classified. For clinicians, this action underscores the regulatory complexity surrounding psychoactive compounds and the distinction between scheduled substances and emerging drugs of abuse that may present in patient populations. The placement highlights how federal scheduling decisions occur independently of cannabis policy developments, meaning that even as cannabis scheduling may evolve, other substances continue to face restrictive classifications that limit research and clinical application. Clinicians should remain aware that patients may encounter or misuse novel synthetic drugs beyond traditional controlled substances, requiring vigilance in substance use screening and counseling. The practical takeaway is that clinicians should stay informed about emerging [controlled substance regulations](https://cedclinic.com/marijuana-rescheduling-clinical-implications/) and educate patients about the dangers of novel synthetic drugs while recognizing that federal policy on different substances, including cannabis, may move on separate trajectories. Clinical Perspective The DEA’s emergency scheduling of 4-fluoroamphetamine reflects ongoing efforts to address novel psychoactive substances that evade existing drug regulations, though clinicians should recognize that scheduling decisions are primarily regulatory and enforcement-based rather than derived from robust clinical safety or efficacy data. While the placement aims to prevent [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) harms, the limited peer-reviewed literature on this specific compound’s human effects means that clinicians managing acute intoxication or withdrawal will likely rely on extrapolation from structurally similar amphetamines and real-time toxicology consultation rather than established clinical protocols. The rapid emergence and scheduling of designer drugs underscores a persistent gap between regulatory classification and clinical evidence, creating challenges for emergency medicine and addiction specialists who must treat patients without well-characterized pharmacodynamic or toxicological profiles. Clinicians should maintain awareness of evolving novel psychoactive substance schedules through DEA alerts and poison control networks, and 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+4-Fluoroamphetamine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F01%2F15%2F2026-00633%2Fschedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F01%2F15%2F2026-00633%2Fschedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+4-Fluoroamphetamine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F01%2F15%2F2026-00633%2Fschedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Further Reading CED Clinic Blog[Semaglutide vs Tirzepatide Comparison: Which Works Better and Why](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) Evidence Watch[From Analgesia to Synaptic Remodeling: A Systematic Review of Acetaminophen’s Neuromodulatory Effects.](https://cedclinic.com/acetaminophen-neuroplasticity-review-neuromodulatory-effects/) Research Digest[Research Digest: 4 Recent Studies – April 09, 2026](https://cedclinic.com/4-recent-cannabis-research-studies-april-2026/) Related Articles - [Mystery ‘Fake Pot’ Liquid Seized In Washington Tagged As New JWH-018-S, Feds Say](https://cedclinic.com/synthetic-cannabinoids-patient-safety-regulation/) - [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) - [High Marijuana Taxes Don’t Effectively Deter Use, Study Shows, Contrary To NYT Editorial …](https://cedclinic.com/cannabis-tax-increases-patient-use-study-insights/) 📰 Source: [https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i](https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Explore the DEA's scheduling of CUMYL-PEGACLONE and its regulatory impact as a Schedule I substance. [Read More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Detailed analysis of MDMB-4en-PINACA's placement in Schedule I and its implications for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). [Learn More](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) Review the DEA's decision to schedule Diphenidine in Schedule I and its relevance to substance abuse monitoring. [Discover More](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).